Long-term prospective population PK study in GIST patients - Letter

Clinical Cancer Research

Volumn 19, Issue 4, 2013, Pages 949-

  Chatelut, Etienne ^a   Gandia, Peggy ^a   Gotta, Verena ^b,c   Widmer, Nicolas ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; OROSOMUCOID;

CANCER SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; MALE; PIPERAZINES; PYRIMIDINES;

EID: 84874093024     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3445     Document Type: Letter

References (5)

1. Eechoute K, FranssonMN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012;18:5780-7.
2. Gardner ER, Sparreboom A, Verweij J, Figg WD. Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther 2008;7:412-5.
3. Haouala A, Widmer N, Guidi M, Montemurro M, Leyvraz S, Buclin T, et al. Prediction of free imatinib concentrations based on total plasma levels in gist patients. Br J Clin Pharmacol. 2012 Aug 15. [Epub ahead of print].
4. Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006;12:6073-78.
5. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec- Rychter M, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008;98:1633-40.